FR2933979B1 - Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine - Google Patents

Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine

Info

Publication number
FR2933979B1
FR2933979B1 FR0854794A FR0854794A FR2933979B1 FR 2933979 B1 FR2933979 B1 FR 2933979B1 FR 0854794 A FR0854794 A FR 0854794A FR 0854794 A FR0854794 A FR 0854794A FR 2933979 B1 FR2933979 B1 FR 2933979B1
Authority
FR
France
Prior art keywords
triazine
preparation
application
human therapy
uracil derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0854794A
Other languages
English (en)
French (fr)
Other versions
FR2933979A1 (fr
Inventor
Isabelle Leroy
Passelaigue Elisabeth Dupont
Karine Valeille
Yves Rival
Didier Junquero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0854794A priority Critical patent/FR2933979B1/fr
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to JP2011517863A priority patent/JP5599788B2/ja
Priority to PCT/EP2009/058609 priority patent/WO2010006962A1/en
Priority to EP09797466.1A priority patent/EP2328886B1/en
Priority to US13/054,293 priority patent/US8618287B2/en
Priority to TW098123438A priority patent/TW201006815A/zh
Priority to ARP090102680A priority patent/AR072510A1/es
Publication of FR2933979A1 publication Critical patent/FR2933979A1/fr
Application granted granted Critical
Publication of FR2933979B1 publication Critical patent/FR2933979B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR0854794A 2008-07-15 2008-07-15 Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine Expired - Fee Related FR2933979B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0854794A FR2933979B1 (fr) 2008-07-15 2008-07-15 Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
PCT/EP2009/058609 WO2010006962A1 (en) 2008-07-15 2009-07-07 Derivatives of triazines and uracils, their preparation and their application in human therapeutics
EP09797466.1A EP2328886B1 (en) 2008-07-15 2009-07-07 Derivatives of triazines and uracils, their preparation and their application in human therapeutics
US13/054,293 US8618287B2 (en) 2008-07-15 2009-07-07 Derivatives of triazines and uracils, their preparation and their application in human therapeutics
JP2011517863A JP5599788B2 (ja) 2008-07-15 2009-07-07 トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用
TW098123438A TW201006815A (en) 2008-07-15 2009-07-10 Derivatives of triazines and uracils, their preparation and their application in human therapeutics
ARP090102680A AR072510A1 (es) 2008-07-15 2009-07-15 Derivados de triazinas y de uracilos, su preparacion y su aplicacion en terapeutica humana

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0854794A FR2933979B1 (fr) 2008-07-15 2008-07-15 Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine

Publications (2)

Publication Number Publication Date
FR2933979A1 FR2933979A1 (fr) 2010-01-22
FR2933979B1 true FR2933979B1 (fr) 2012-08-24

Family

ID=40394394

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0854794A Expired - Fee Related FR2933979B1 (fr) 2008-07-15 2008-07-15 Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine

Country Status (7)

Country Link
US (1) US8618287B2 (enExample)
EP (1) EP2328886B1 (enExample)
JP (1) JP5599788B2 (enExample)
AR (1) AR072510A1 (enExample)
FR (1) FR2933979B1 (enExample)
TW (1) TW201006815A (enExample)
WO (1) WO2010006962A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664873B (zh) 2009-12-30 2016-06-15 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
FR2958935B1 (fr) 2010-04-19 2012-06-22 Pf Medicament Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
CN104803971B (zh) * 2014-01-24 2021-11-30 深圳信立泰药业股份有限公司 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物
CN105017213B (zh) * 2014-04-30 2017-11-14 成都苑东生物制药股份有限公司 尿嘧啶衍生物
CN107074823B (zh) * 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
TWI884745B (zh) * 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3914593A4 (en) 2019-01-24 2022-11-02 Yumanity Therapeutics, Inc. CONNECTIONS AND USES THEREOF
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
TWI763147B (zh) 2019-11-26 2022-05-01 大陸商昆藥集團股份有限公司 1，2，4-三嗪-3，5-二酮類化合物及其製備方法和應用
WO2024102455A1 (en) * 2022-11-09 2024-05-16 Emory University Non-covalent inhibitors of coronavirus main protease
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973573A (ja) * 1982-09-09 1984-04-25 ワ−ナ−−ランバ−ト・コンパニ− ジアミノピリミジン化合物
US20050256159A1 (en) * 2002-10-11 2005-11-17 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
AU2006326815A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase

Also Published As

Publication number Publication date
WO2010006962A1 (en) 2010-01-21
EP2328886B1 (en) 2016-12-28
US20110118266A1 (en) 2011-05-19
FR2933979A1 (fr) 2010-01-22
US8618287B2 (en) 2013-12-31
JP2011528007A (ja) 2011-11-10
AR072510A1 (es) 2010-09-01
TW201006815A (en) 2010-02-16
JP5599788B2 (ja) 2014-10-01
EP2328886A1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
FR2933979B1 (fr) Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2911604B1 (fr) Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2915199B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyrimidine-carboxamides, leur preparation et leur application en therapeutique.
FR2915198B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2928924B1 (fr) Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique
FR2928922B1 (fr) Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique
BR112012000370A2 (pt) derivados de 1,2,4-tiazolidin-3-ona e seus usos no tratamento de câncer
FR2928921B1 (fr) Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
FR2967674B1 (fr) Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
FR2948939B1 (fr) Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2917412B1 (fr) Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2958935B1 (fr) Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
FR2891828B1 (fr) Derives de la 1-amino-phtalazine substituee, leur preparation et leur application en therapeutique
FR2925901B1 (fr) DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2932481B1 (fr) Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
FR2891825B1 (fr) Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique
FR2884822B1 (fr) Derives de triazines, leur preparation et leur application en therapeutique
FR2925903B1 (fr) DERIVES 6-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Legal Events

Date Code Title Description
CJ Change in legal form
PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20180330